New Journal Article Highlights Challenges, Opportunities for Next-Generation Point-of-Care Testing Technologies
Dr. Laura Mazzola, Wave 80’s Senior Vice President of Global Initiatives, co-authors analysis of impact and opportunities for POC diagnostics.
San Francisco, California, March 7, 2012. A new scientific publication appearing today highlights the promise of emerging point-of-care testing technologies to improve individual patient outcomes and public health, while also shedding light on the barriers posed by a host of barriers ranging from global regulatory process discord to outdated reimbursement practices to infrastructure-related product distribution inefficiencies in developing countries.More
Wave 80 awarded $7.5 million NIH contract for HIV rapid virus testing
Next-generation point-of-care molecular diagnostic system meets challenges of detecting acute infections, monitoring recipients of candidate vaccines, and diagnosing infants born to HIV-infected mothers.
San Francisco, California, October 28 2009. Wave 80 Biosciences, Inc. today announced that it has been awarded a USD 7.5 million contract (HHSN272200900029C) by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, Department of Health and Human Services, for rapid HIV/AIDS nucleic acid testing systems for use in low resource settings.More
Wave 80 chief executive to address microsystems commercialization conference in Chongqing, China
Talk will highlight evolving challenges and opportunities in global health.
San Francisco, California, October 14 2009. Daniel J. Laser, Ph.D., Wave 80's Chief Executive Officer and President, will speak at the 3rd International Workshop on Innovation and Commercialization of Micro and Nano Technology (ICMAN 2009), the company announced today.More
Wave 80, Magnisense partner in infectious disease diagnostics and patient monitoring
Collaboration to explore new ways of using magnetic detection in high-performance enclosed-cartridge-format assays.
Paris, France and San Francisco, California, March 5, 2009. Magnisense (www.magnisense.com) and Wave 80 Biosciences (www.wave80.com) today announced the establishment of a new strategic partnership to explore synergies between the companies’ industry-leading technology platforms, MIAtek™ magnetic detection technology and SCATM assay cartridge technology.More
Wave 80 presents poster at multiple sclerosis meeting
Exploring new methods of optimizing therapies.
San Francisco, California, January 3, 2009. Wave 80's Senior Director of Applied Cell Physiology, Dr. Andrew Arsham, will present a poster at the upcoming Keystone Symposium on Multiple Scleroris, to be held in Santa Fe, New Mexico from January 21-26, 2009, the company announced today.More
Wave 80 initiates new program in biomarker-based stroke patient stratification
New approach to guiding therapy holds promise for improving patient outcomes in ischemic stroke.
San Francisco, CA, July 9, 2008 – Researchers at Wave 80 have commenced a new program exploring the use of circulating biomarkers to inform clinical decisionmaking in acute stroke by predicting which patients are most likely to benefit from current and emerging treatments, the company announced today.
"Acute ischemic stroke is an area of high unmet need," said Daniel Laser, Ph.D., Wave 80's CEO. "This program leverages key elements of the biomarker measurement technology platform Wave 80 developed for the U.S. military to tackle the extraordinary challenge of guiding stroke therapy within the narrow window of opportunity when administering therapy is most effective."More
Wave 80, Siemens team up on HIV viral load measurement
With NIH support, initiative seeks to develop innovative tools for guiding antiretroviral therapy
San Francisco, California and Tarrytown, New York, October 19, 2007 – Targeting a major area of need in the global fight against HIV/AIDS, Wave 80 and Siemens Medical Solutions Diagnostics today announced the beginning of a new research initiative focused on technologies to complement pharmaceutical strategies for helping patients diagnosed with HIV lead longer, more productive lives.More
Wave 80 malaria diagnostic selected for oral presentation at prestigious Oak Ridge conference
Emerging technologies forum will showcase research on ultraminature device for multiplexed measurement of malarial disease markers in fingerstick blood samples
San Francisco, California, March 7, 2007 – Daniel Laser,, Ph.D., Wave 80’s CEO and President, will give an invited talk at the 39th Annual Oak Ridge conference: Harnessing New Technology for Clinical Diagnostics. The annual Oak Ridge meeting is sponsored by American Association for Clinical Chemistry and brings together thought leaders in diagnostics methods and instrumentation. The 2007 meeting will be held in St. Louis, Missouri on April 18-19, 2007.More